- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01498692
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels (PLATINUM SV)
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Small Vessel Sub-trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The wide-spread use of drug-eluting stents (DES) has evolved as standard of care in de novo lesions. The proposed study will evaluate the safety and effectiveness of PROMUS Element for the treatment of de novo atherosclerotic lesions in native coronary arteries. The study design is consistent with the draft guidance for industry titled, "Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies" (March 2008).
During the trial, thienopyridines must be administered according to the 2007 American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography and Interventions (SCAI) guidelines, which recommended that clopidogrel (75 mg daily) or ticlopidine (250 mg twice daily) be prescribed after stent implantation for at least 6 months in all patients, and for at least 12 months in patients who are not at high risk of bleeding. For sites in the United States, the use of prasugrel is not allowed as part of the PLATINUM Clinical Trial. For sites in other countries, prasugrel may be prescribed according to its approved dosing in countries in which it is available. For patients taking aspirin daily a loading dose is recommended; for patients who have not been taking aspirin daily, aspirin must be administered as a loading dose. Patients continue to take aspirin indefinitely to reduce the risk of thrombosis.
This PLATINUM Small Vessel study is a sub-trial associated with the PLATINUM Workhorse Randomized Controlled Trial, which is registered under NCT00823212.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Clayton, Australia, VIC 3168
- Monash Medical Centre
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- St. Vincent's Hospital
-
-
-
-
-
Genk, Belgium, 3600
- Ziekenhuis Oost Limburg
-
Leuven, Belgium, B-3000
- Uz Gasthuisberg
-
-
-
-
-
Toulouse, France, 31076
- Clinique PASTEUR
-
-
Cedex 9
-
Toulouse, Cedex 9, France, 31059
- Centre Hôpital Universitaire Rangueil
-
-
-
-
Kanagawa-ken
-
Kamakura-shi, Kanagawa-ken, Japan
- Shonan Kamakura General Hospital
-
-
Osaka
-
Osaka-shi, Osaka, Japan
- Sakurabashi Watanabe Hospital
-
-
-
-
-
Takapuna, New Zealand, 0622
- North Shore Hospital
-
-
-
-
California
-
Bakersfield, California, United States, 93301
- Bakersfield Memorial Hospital
-
-
Florida
-
Ocala, Florida, United States, 34471
- MediQuest Research at Munroe Regional Medical Center
-
Orlando, Florida, United States, 32803
- Florida Hospital
-
-
Illinois
-
Springfield, Illinois, United States, 62701
- St. John's Hospital
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Jewish Hospital & St. Mary's Healthcare
-
-
Michigan
-
Petoskey, Michigan, United States, 49770
- Northern Michigan Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Abbott Northwestern Hospital
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27401
- Moses H. Cone Memorial Hospital/LeBauer Cardiovascular Research Foundation
-
Raleigh, North Carolina, United States, 27610
- Wake Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Lindner Center for Research and Education at the Christ Hospital
-
Columbus, Ohio, United States, 43124
- Ohio Health Research and Innovation Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Oklahoma Foundation for Cardiovascular Research
-
-
Texas
-
Dallas, Texas, United States, 75226
- Baylor Heart & Vascular Hospital
-
San Antonio, Texas, United States, 78229
- TexSAn Heart Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must be at least 18 years of age
- Patient (or legal guardian) understands study requirements and treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
- For patients less than 20 years of age enrolled at a Japanese site, patient and patient's legal representative must provide written informed consent before any study-specific tests or procedures are performed
- Patient is eligible for percutaneous coronary intervention (PCI)
- Patient has documented stable angina pectoris or documented silent ischemia; or unstable angina pectoris
- Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
- Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
- Patient is willing to comply with all protocol-required follow-up evaluations
Angiographic Inclusion Criteria (visual estimate):
- Target lesion must be a de novo lesion located in a native coronary artery with a visually estimated reference vessel diameter ≥2.25 mm and <2.5 mm. Target lesion length must measure ≤28 mm by visual estimate. Target lesion must be located in a major coronary artery or branch with visually estimated stenosis ≥50% and <100% with Thrombolysis In Myocardial Infarction (TIMI) flow >1.
Exclusion Criteria:
- Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index procedure) and has elevated enzymes at time of index procedure as follows.
Patients are excluded if any of the following criteria are met at time of the index procedure.
- If creatine kinase-myoglobin band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of CK Total.
- If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
If CK Total/CK MB are not used and Troponin is, patients are excluded if the following criterion is met at time of index procedure.
- Troponin >1× ULN with at least one of the following.
- Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg, >1 mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
- Development of pathological Q waves in the ECG; or
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling/randomizing the patient.
- Patient has received an organ transplant or is on a waiting list for an organ transplant
- Patient is receiving or scheduled to receive chemotherapy within 30 days before or after index procedure
- Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
- Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
- Patient has platelet count <100,000 cells/mm3 or >700,000 cells/mm3
- Patient has white blood cell (WBC) count <3,000 cells/mm3
- Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
- Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine clearance <50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dl)*72])
- Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
- Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index procedure
- Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to index procedure
- Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index procedure
- Planned or actual target vessel(s) treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter immediately prior to stent placement
- Planned PCI or CABG after index procedure
- Patient previously treated at any time with coronary intravascular brachytherapy
- Patient has a known allergy to the study stent system or protocol-required concomitant medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated
- Patient has active peptic ulcer or active gastrointestinal (GI) bleeding
Patient has one of the following.
- Other serious medical illness (eg, cancer, congestive heart failure) that may reduce life expectancy to less than 24 months
- Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)
- Planned procedure that may cause non-compliance with protocol or confound data interpretation
- Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
- Patient intends to participate in another investigational drug or device clinical trial within 12 months after index procedure
- Patient with known intention to procreate within 12 months after index procedure (Women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure.)
- Patient is a woman who is pregnant or nursing (A pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)
- Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target lesion, which will be treated during the index procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PROMUS Element
Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
|
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Lesion Failure (TLF)
Time Frame: 12 Months
|
Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
The primary analysis set for the non-inferiority testing of the primary endpoint is the per-protocol analysis set.
All randomized participants who received their assigned treatment are included in the per-protocol analysis set.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Cause Mortality
Time Frame: 6 months
|
6 months
|
|
All Cause Mortality
Time Frame: 12 months
|
12 months
|
|
All Cause Mortality
Time Frame: 30 days
|
30 days
|
|
Target Lesion Failure (TLF)
Time Frame: 6 Months
|
Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
|
6 Months
|
Target Lesion Failure (TLF)
Time Frame: 30 Days
|
Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
|
30 Days
|
Target Vessel Failure (TVF)
Time Frame: 12 Months
|
Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel.
For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
|
12 Months
|
Target Vessel Failure (TVF)
Time Frame: 6 Months
|
Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel.
For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
|
6 Months
|
Target Vessel Failure (TVF)
Time Frame: 30 Days
|
Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel.
For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
|
30 Days
|
Myocardial Infarction (MI) Related to the Target Vessel
Time Frame: 12 Months
|
New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin >upper limit of normal(ULN); if no new Q-waves total CK levels >3×ULN (peri-percutaneous coronary intervention [PCI]) or >2×ULN (spontaneous) with elevated CK-MB or troponin >3×ULN (peri-PCI) or >2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality.
Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×ULN
|
12 Months
|
Myocardial Infarction (MI) Related to the Target Vessel
Time Frame: 6 months
|
New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin >upper limit of normal(ULN); if no new Q-waves total CK levels >3×ULN (peri-percutaneous coronary intervention [PCI]) or >2×ULN (spontaneous) with elevated CK-MB or troponin >3×ULN (peri-PCI) or >2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality.
Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×ULN
|
6 months
|
Myocardial Infarction (MI) Related to the Target Vessel
Time Frame: 30 days
|
New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin >upper limit of normal(ULN); if no new Q-waves total CK levels >3×ULN (peri-percutaneous coronary intervention [PCI]) or >2×ULN (spontaneous) with elevated CK-MB or troponin >3×ULN (peri-PCI) or >2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality.
Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×ULN
|
30 days
|
Cardiac Death Related to the Target Vessel
Time Frame: 12 months
|
Defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above.
|
12 months
|
Cardiac Death Related to the Target Vessel
Time Frame: 6 months
|
Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
|
6 months
|
Cardiac Death Related to the Target Vessel
Time Frame: 30 days
|
Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
|
30 days
|
Target Lesion Revascularization (TLR)
Time Frame: 12 months
|
Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
|
12 months
|
Target Lesion Revascularization (TLR)
Time Frame: 6 months
|
Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
|
6 months
|
Target Lesion Revascularization TLR)
Time Frame: 30 days
|
Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
|
30 days
|
Target Vessel Revascularization (TVR)
Time Frame: 12 months
|
Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.
|
12 months
|
Target Vessel Revascularization (TVR)
Time Frame: 6 months
|
Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.
|
6 months
|
Target Vessel Revascularization (TVR)
Time Frame: 30 days
|
Any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.
|
30 days
|
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC)Definition
Time Frame: 24 hours
|
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points.
Time 0 is the time point after the guide catheter has been removed.
Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)
|
24 hours
|
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
Time Frame: >24 hr-30 days
|
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points.
Time 0 is the time point after the guide catheter has been removed.
Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)
|
>24 hr-30 days
|
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
Time Frame: >30 days-1 year
|
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points.
Time 0 is the time point after the guide catheter has been removed.
Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)
|
>30 days-1 year
|
Acute Technical Success
Time Frame: During the index procedure (minutes)
|
Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent
|
During the index procedure (minutes)
|
Clinical Procedural Success
Time Frame: Duration of Hospital Stay (average 1-2 days)
|
Defined as mean lesion diameter stenosis <30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital MI, TVR, or cardiac death.
|
Duration of Hospital Stay (average 1-2 days)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Teirstein PS, Meredith IT, Feldman RL, Rabinowitz AC, Cannon LA, Lee TC, Dens J, Dubois CL, Mooney MR, Pompili VJ, Saito S, Allocco DJ, Dawkins KD, Stone GW. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions. Catheter Cardiovasc Interv. 2015 Feb 1;85(2):207-15. doi: 10.1002/ccd.25565. Epub 2014 Jul 4.
- Kelly CR, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Rabinowitz A, Carrie D, Pompili V, Bouchard A, Saito S, Allocco DJ, Dawkins KD, Stone GW. Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial. JACC Cardiovasc Interv. 2017 Dec 11;10(23):2392-2400. doi: 10.1016/j.jcin.2017.06.070.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S2046A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on PROMUS Element Coronary Stent System
-
Boston Scientific CorporationUnknown
-
Boston Scientific CorporationCompletedCoronary Artery DiseaseSpain, Belgium, France, Australia, United Kingdom, Sweden, New Zealand, Denmark, Poland
-
University Hospital HeidelbergCompletedCoronary Artery Disease
-
Thorax Centrum TwenteUnknownCoronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Unstable Angina Pectoris | Coronary Stenosis | Coronary RestenosisNetherlands
-
Yonsei UniversityUnknown
-
Yonsei UniversityCompleted
-
European Cardiovascular Research CenterUnknownIschemic Heart Disease | Coronary Artery StenosisSpain, Germany, France, United Kingdom, Italy, Netherlands, Macedonia, The Former Yugoslav Republic of, Switzerland
-
Micell TechnologiesYale Cardiovascular Research Group; North American Science Associates Inc.; Baim...Not yet recruiting
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital with Nanjing Medical University; Shanghai East... and other collaboratorsUnknownAcute Myocardial InfarctionChina
-
A.O. Ospedale Papa Giovanni XXIIIBoston Scientific Corporation; Case Western Reserve UniversityCompletedCoronary Artery DiseaseItaly